Vertex Pharmaceuticals Inc (VRTX)
481.24
+1.35
(+0.28%)
USD |
NASDAQ |
Aug 23, 16:00
481.24
0.00 (0.00%)
After-Hours: 20:00
Vertex Pharmaceuticals Revenue (Quarterly): 2.646B for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 2.646B |
March 31, 2024 | 2.691B |
December 31, 2023 | 2.518B |
September 30, 2023 | 2.484B |
June 30, 2023 | 2.493B |
March 31, 2023 | 2.375B |
December 31, 2022 | 2.303B |
September 30, 2022 | 2.334B |
June 30, 2022 | 2.196B |
March 31, 2022 | 2.098B |
December 31, 2021 | 2.073B |
September 30, 2021 | 1.984B |
June 30, 2021 | 1.793B |
March 31, 2021 | 1.724B |
December 31, 2020 | 1.628B |
September 30, 2020 | 1.538B |
June 30, 2020 | 1.524B |
March 31, 2020 | 1.515B |
December 31, 2019 | 1.413B |
September 30, 2019 | 949.83M |
June 30, 2019 | 941.29M |
March 31, 2019 | 858.44M |
December 31, 2018 | 870.11M |
September 30, 2018 | 784.54M |
June 30, 2018 | 752.16M |
Date | Value |
---|---|
March 31, 2018 | 640.80M |
December 31, 2017 | 651.63M |
September 30, 2017 | 578.16M |
June 30, 2017 | 544.14M |
March 31, 2017 | 714.72M |
December 31, 2016 | 458.71M |
September 30, 2016 | 413.78M |
June 30, 2016 | 431.61M |
March 31, 2016 | 398.08M |
December 31, 2015 | 417.94M |
September 30, 2015 | 309.82M |
June 30, 2015 | 166.08M |
March 31, 2015 | 138.51M |
December 31, 2014 | 144.56M |
September 30, 2014 | 178.99M |
June 30, 2014 | 138.42M |
March 31, 2014 | 118.45M |
December 31, 2013 | 351.16M |
September 30, 2013 | 221.70M |
June 30, 2013 | 310.75M |
March 31, 2013 | 328.37M |
December 31, 2012 | 333.99M |
September 30, 2012 | 336.01M |
June 30, 2012 | 418.30M |
March 31, 2012 | 438.74M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
949.83M
Minimum
Sep 2019
2.691B
Maximum
Mar 2024
2.014B
Average
2.085B
Median
Revenue (Quarterly) Benchmarks
Eli Lilly and Co | 11.30B |
Regeneron Pharmaceuticals Inc | 3.547B |
AbbVie Inc | 14.46B |
Amgen Inc | 8.388B |
Intellia Therapeutics Inc | 6.957M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -3.594B |
Total Expenses (Quarterly) | 1.711B |
EPS Diluted (Quarterly) | -13.92 |
Enterprise Value | 118.06B |
Gross Profit Margin (Quarterly) | 85.94% |
Profit Margin (Quarterly) | -135.8% |
Earnings Yield | -0.42% |
Operating Earnings Yield | 3.35% |
Normalized Earnings Yield | 2.476 |